Trial Profile
A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 459
- Sponsors Bristol-Myers Squibb
- 21 Mar 2024 The trial has been completed in Sweden, according to European Clinical Trials Database
- 17 Mar 2024 The trial has been completed in France, according to European Clinical Trials Database.
- 15 Mar 2024 Status changed from active, no longer recruiting to completed.